Two big drug failures in the past month have investors worried about a whole field of medicine. Novartis and Novo Nordisk both lost trials for heart drugs aimed at the same target.
Novartis Loses Its Trial
On the eve of Labor Day, Novartis announced that its cardiac therapy, pelacarsen, had failed in a seven-year clinical trial. The drug was meant to lower lipoprotein a, or Lp(a), a kind of fat that builds up in some people and raises the risk of heart attacks and strokes.
Lp(a) runs at elevated levels in an estimated 20% of people. Novartis was the first stab at a new type of cardiovascular treatment, and the failure has set off concern that other companies working on similar drugs might be heading toward the same wall.
Novo Follows With Its Own Loss
Not long after Novartis, Novo Nordisk followed with its own setback. The company’s drug was aimed at lowering Lp(a).
Together, the two losses hit the market hard. The question facing the industry is whether the whole field of Lp(a) drugs can survive these setbacks.
What Lp(a) Does
Lp(a) is a type of lipid, a fat found in the blood. When levels get too high, the risk of serious heart problems rises sharply.
An estimated 20% of people carry abnormally high levels of Lp(a). That means a large share of the population could benefit from a drug that lowers it — which is why so many companies are chasing the same target.
Who Else Is Chasing Lp(a)
Multiple drug companies are investing heavily in Lp(a) medications. Novartis was the first stab at a new type of cardiovascular treatment, but it was not alone in the race.
The stakes are high. Companies have poured billions of dollars into their own Lp(a) drugs.
The Industry Reaction
The failures could have a chilling effect across the industry. One loss could make others wary of following the same path.
For patients who carry high Lp(a), the news is sobering. A drug that promised protection against heart attack and stroke has fallen short.
What Happens Next
The industry will need to answer several questions:
- Can Novo Nordisk’s drug still succeed elsewhere?
- Are the other Lp(a) drugs in development actually different enough to work?
- Will investors pull back funding from the whole field?
The answers will shape how the industry moves forward. For now, the failures stand as a cautionary note for anyone watching the heart drug space.
Key Facts
- Novartis’ pelacarsen failed in a seven-year trial
- Novo Nordisk also lost its own Lp(a) drug
- About 20% of people have elevated Lp(a) levels
- Multiple drug companies are investing billions in Lp(a) treatments
The field has lost two major bets in quick succession. Whether it can recover depends on what comes next — and what the remaining companies manage to prove.
Source: statnews.com
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.